The recent explosion in the use of social media has led to a rapidly changing landscape in pharmacovigilance. More and more patients are content to share health information online and often on entirely open access sites. Such information remains mostly untapped and there are questions as to its usefulness in generating signals of emerging drug safety issues.
West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK
Correspondence to Christopher Anton, West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham B18 7QH, UK. Tel: +44 121 507 5672; e-mail: email@example.com
Editor: R E Ferner, MSc, MD, FRCP, Director of the West Midlands Centre for Adverse Drug Reaction Reporting and Consultant Physician at City Hospital, Birmingham, UK. Assistant Editor: Mr C Anton, MA, MEng. Editorial Board: Australia: Dr M Kennedy, Professor G M Shenfield, Denmark: Professor J S Schou; England: Dr J K Aronson; India: Professor N Gogtay; Netherlands: Professor C J van Boxtel, Dr B H Ch Stricker; New Zealand: Dr T Maling; Scotland: Dr D N Bateman; Wales: Professor P A Routledge.